Novo Nordisk is doubling down on its obesity drug pipeline, agreeing to pay up to $2.6 billion to China's Jiangsu Hengrui Pharmaceuticals for global rights (excluding mainland China, Hong Kong, Macao, and Taiwan) to HRS-1596 — an experimental oral GLP-1 weight-loss pill with potential for once-weekly dosing. The deal includes a $300 million upfront payment plus up to $2.3 billion in milestone payments tied to development, regulatory, and commercial progress.

The move comes as Novo's shares have tumbled more than 70% from record highs amid stiff competition from Eli Lilly's rival GLP-1 therapies. Analysts view the deal as a longer-term pipeline play rather than a near-term competitive game-changer. Novo is also developing another obesity candidate, UBT251, with United Laboratories International, which showed up to 19.7% mean weight loss after 24 weeks in trials.

By the Numbers:

• ~250 Chinese GLP-1 drug candidates currently in development
• $300M upfront + up to $2.3B in milestones = $2.6B total deal value
• Novo shares down 70%+ from record highs
• Global GLP-1 market projected to hit ~$100B in annual sales within a decade

Why it matters: This deal underscores China's rapidly expanding role in global obesity drug development and Novo's urgency to diversify its pipeline ahead of looming patent expirations — with a once-weekly oral GLP-1 potentially reshaping patient convenience and market dynamics.